Basic Stemetil Information

• INN (International Nonproprietary Name): Prochlorperazine
• Brand Names Available In United Kingdom: Stemetil; Compazine (brand availability varies); various generics marketed by Teva, Sandoz and other manufacturers
• ATC Code: N05AB04
• Forms & Dosages: Tablets 5 mg and 10 mg (5 mg common in community); suppositories 25 mg; injectable ampoules 5 mg/mL and 12.5 mg/mL; oral solution/syrup 5 mg/5 mL
• Manufacturers In United Kingdom: Teva, Sandoz, Fresenius Kabi, and other generic suppliers (Heritage Pharmaceuticals and Medochemie are among global manufacturers)
• Registration Status In United Kingdom: Licensed products available; prescription-only medicine supplied via MA holders and hospital formularies
• OTC / Rx Classification: Prescription Only (Rx)

Major 2022–2025 Studies

What does recent research tell us about Stemetil and prochlorperazine?

Several pragmatic trials and systematic reviews dated 2022–2025 examined prochlorperazine primarily for acute migraine rescue, postoperative nausea and palliative-care emesis.

Large new randomised controlled trials are few in this period, with most evidence coming from pragmatic designs and pharmacoepidemiology analyses.

UK practice guidance still cites older RCTs, but recent comparative work focuses on buccal formulations such as Buccastem and Stemetil buccal versus oral or injectable routes.

Those buccal options are studied for faster onset, particularly in emergency and urgent-care pathways.

Trials and audits in emergency departments tested time-to-relief as a pragmatic outcome rather than long-term efficacy.

Research trend therefore highlights formulation and route rather than wholesale superiority over other antiemetics.

Clinicians in the UK take these findings into account when choosing buccal or parenteral options in acute settings.

Main Outcomes

Which benefits were consistently reported in recent work?

Prochlorperazine shows a reliable antiemetic effect compared with placebo across acute-emesis indications.

Comparative analyses found non-inferiority to metoclopramide for many uses, including short-term control of severe nausea.

Buccal and parenteral formulations shorten time-to-relief compared with oral tablets in emergency contexts.

Community treatment still relies on 5 mg tablets as the mainstay for routine nausea control.

These outcomes support continuing use of prochlorperazine where rapid symptom control or multiple routes are needed.

Safety Observations

What safety signals should prescribers and patients watch for?

Contemporary pharmacovigilance emphasises extrapyramidal reactions, sedation and QT-prolongation risk when prochlorperazine is combined with other agents.

Elderly populations exhibit higher adverse-event reporting and generally require dose reductions.

Guidance urges caution with co-prescription of QT-prolonging drugs and with patients at baseline risk of arrhythmia.

Early monitoring for dystonic reactions and akathisia is recommended after initiation, especially with parenteral dosing.

Layman’s Explanation

How does Stemetil calm nausea in simple terms?

Prochlorperazine is a phenothiazine originally developed as an antipsychotic that has strong antiemetic properties.

The drug acts on a part of the brain called the chemoreceptor trigger zone to reduce signals that provoke vomiting.

That calming of the brain’s vomiting centre explains why it helps both sudden severe nausea and, at higher doses, some psychotic symptoms.

Because it affects other receptors, drowsiness and dry mouth are commonly experienced.

Scientific Breakdown

What is the pharmacology behind prochlorperazine?

Prochlorperazine is classified under ATC code N05AB04 as a phenothiazine with a piperazine structure.

Its primary action is antagonism of dopamine D2 receptors in the chemoreceptor trigger zone, which reduces emetic signalling.

It also has weaker antagonism at histamine H1 and muscarinic receptors, which contributes to sedation and anticholinergic effects.

These pharmacodynamic properties explain both therapeutic actions and many side effects such as drowsiness and dry mouth.

Pharmacokinetics & Formulations

How quickly does each form act and why choose one over another?

Tablets (commonly 5 mg) are the usual community option and have a standard oral absorption profile.

Suppositories (25 mg) and oral solution can be used when swallowing is not possible or rapid GI absorption is unreliable.

Injectable ampoules, typically 5 mg/mL or 12.5 mg/mL, offer the fastest onset for IM/IV administration in hospital.

Buccal formulations such as Buccastem and Stemetil buccal are designed for rapid mucosal uptake and are useful for acute migraine rescue.

United Kingdom Approvals

What is Stemetil licensed for in the UK?

In the United Kingdom Stemetil (prochlorperazine) is authorised as a prescription-only medicine for severe nausea and vomiting and for short-term management of psychotic disorders and anxiety.

Dosage forms available include 5 mg tablets and injectable ampoules, and generics from Teva, Sandoz and others are widely supplied.

Hospital formularies commonly list parenteral forms for emergency use and palliative care.

Notable Off-Label Trends

Which uses are common but off-label in UK practice?

Off-label but common uses include acute migraine rescue using buccal tablets, treatment of severe vertigo and refractory palliative-care nausea.

Emergency departments frequently administer IM or IV prochlorperazine for rapid symptom control.

It is also used as an adjunct when ondansetron is contraindicated or inadequate in chemotherapy-induced nausea.

Regulatory notes recommend limiting duration and exercising caution in elderly patients because of increased mortality risk in dementia-related psychosis.

General Dosing

What are the usual dose ranges for adults?

For adults in the community a common starting dose is 5–10 mg orally three to four times daily for nausea, according to product information.

In hospital IM or IV dosing is typically 5–10 mg once or twice daily for rapid control.

Suppositories are commonly supplied as 25 mg when oral administration is unsuitable.

Condition-Specific Dosing

How is dosing adjusted for specific conditions?

For nausea and vomiting the typical oral dose is 5–10 mg every 6–8 hours as required, with parenteral 5–10 mg IM/IV for rapid relief.

For psychosis short courses often begin at 5–10 mg three to four times daily with specialist titration for longer-term management.

Pediatric dosing is lower and weight-based; a frequently cited approximate is 0.13 mg/kg orally every 6–8 hours, with age-specific licence limits.

Special populations such as the elderly or those with liver or renal impairment require dose reduction and close monitoring.

Contraindications

Who should not take prochlorperazine?

Absolute contraindications include known hypersensitivity to prochlorperazine or other phenothiazines, comatose states and severe CNS depression.

Children under two years of age or under 10 kg should not receive oral therapy unless a specialist authorises it.

Patients with significant bone marrow depression should not receive prochlorperazine.

Relative contraindications include Parkinson’s disease, severe hepatic or renal impairment, epilepsy and severe cardiovascular disease.

Elderly patients require particular caution because of increased mortality reported in dementia-related psychosis.

Adverse Effects

What side effects are most commonly reported?

Common adverse effects are drowsiness, dizziness, blurred vision, dry mouth and constipation.

Orthostatic hypotension and photosensitivity are also reported.

Extrapyramidal symptoms such as acute dystonia, parkinsonism and akathisia are dose-dependent and can be distressing.

Rare but serious events include neuroleptic malignant syndrome and significant QT prolongation.

Baseline cardiovascular history and medication reconciliation are sensible monitoring steps before prescribing.

Food Interactions

Are there dietary restrictions while taking Stemetil?

No major food restrictions are documented in product information.

Alcohol and other sedating substances will potentiate central nervous system depression and should be avoided while taking prochlorperazine.

Patients should be warned that alcohol increases risks of drowsiness and orthostatic symptoms.

Drug Combinations To Avoid

Which medicines increase risk when taken with prochlorperazine?

High-risk combinations include other central nervous system depressants such as benzodiazepines and opioids because of additive sedation and respiratory depression.

Concurrent use with QT-prolonging drugs such as certain macrolide antibiotics, some antipsychotics and antiarrhythmics increases arrhythmia risk.

Co-administration with other dopamine antagonists in Parkinson’s disease should be avoided.

Caution is required with anticholinergic drugs and with medicines that lower seizure threshold, such as some antiepileptics.

Prescribers should check MHRA advice and review CYP interactions in complex polypharmacy.

Patient Experience Analysis

How do patients describe taking prochlorperazine?

Survey data from UK emergency departments and palliative-care audits report high effectiveness for acute nausea control with prochlorperazine.

Many patients describe rapid relief when given parenteral or buccal formulations for acute vomiting.

Across forums the most frequently mentioned adverse experience is sedation and drowsiness, which affects daily activities and driving.

Other common comments are relief from vomiting, bothersome dry mouth and constipation, and occasional vivid reports of dystonic reactions.

Patients value low cost and generic availability but often request clearer counselling on extrapyramidal symptoms and when to seek urgent care.

Providing written information and clear advice on stopping the drug and seeking medical review improves patient confidence.

Distribution & Pricing Landscape

How widely available is Stemetil and what about price?

Prochlorperazine in the form of Stemetil and generics is broadly available across the UK and Europe in tablets, injectable ampoules and suppositories.

Major generics manufacturers include Teva, Sandoz, Fresenius Kabi and Medochemie, with multiple suppliers worldwide.

Low-cost generics dominate primary-care prescriptions and hospital procurement typically sources parenteral forms centrally.

Price volatility can occur during manufacturing shortages, but a wide global manufacturing base mitigates long-term supply gaps.

Buccal formulations such as Buccastem may carry a higher price but are valued for rapid onset in acute migraine rescue.

In our online pharmacy, stemetil is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Comparison Overview

What are reasonable alternatives to prochlorperazine?

Ondansetron, metoclopramide, promethazine and haloperidol are commonly used alternatives depending on the setting and underlying cause of nausea.

Ondansetron, a 5‑HT3 antagonist, is often preferred for chemotherapy and postoperative nausea due to lower EPS risk.

Metoclopramide provides prokinetic effects useful when gastric stasis contributes to nausea.

Promethazine is another phenothiazine with significant sedation, and haloperidol is sometimes used in refractory palliative nausea.

Pros And Cons

How does prochlorperazine stack up against alternatives?

Ondansetron’s advantages are minimal EPS risk and robust evidence in chemo and post‑op settings, but it is more costly.

Metoclopramide shares antiemetic efficacy but carries a similar risk of extrapyramidal symptoms as prochlorperazine.

Promethazine gives strong sedation which may help in some situations but increases anticholinergic and respiratory risks.

Prochlorperazine’s strengths are efficacy, low cost and multiple formulations including tablets, suppositories and injectables.

Its principal weakness is the EPS risk and the need for caution in elderly patients.

International Regulatory Status

How is prochlorperazine classified worldwide?

Prochlorperazine is a prescription-only medicine under ATC classification N05AB04 and is registered across major markets.

The FDA lists generics and older approvals, although some brand names have been discontinued in certain countries.

EMA authorisations cover various formulations in Europe and the drug appears on several national essential medicines lists.

United Kingdom Specifics

What should UK prescribers know about licensing and guidance?

Stemetil and generic prochlorperazine formulations are licenced and supplied in the UK as prescription medicines with parenteral forms on many hospital formularies.

MHRA guidance aligns with product labelling, highlighting strong caution in elderly patients with dementia-related psychosis.

Wide national registration makes the drug accessible but prescriber oversight is required at initiation and for continued use.

Consolidated FAQ

Is Stemetil the same as prochlorperazine?

Yes; Stemetil is a brand name for the active ingredient prochlorperazine (INN).

Can I take it for migraine?

In the UK prochlorperazine, including buccal forms, is commonly used for acute migraine rescue, but local formularies should be checked for Buccastem availability.

Is it safe in pregnancy?

Use only if the expected benefit outweighs the risk and consult maternity-prescribing guidance and specialist advice.

Can I drive and drink alcohol?

Avoid driving if sedated and do not consume alcohol as it increases central nervous system depression.

What should I do for dystonia?

Seek urgent medical care; healthcare settings typically treat acute dystonic reactions with anticholinergic agents such as procyclidine.

How is overdose managed?

Management is supportive with monitoring of respiratory and cardiovascular status and activated charcoal if presentation is early; there is no specific antidote.

Dosage-Form Imagery (Recommended Visuals)

Which pictures help patients and staff recognise products?

Recommended visuals include a 5 mg tablet image labelled with the INN prochlorperazine and strength and a buccal tablet package such as Buccastem or Stemetil buccal for emergency migraine use.

A suppository image for 25 mg and an injectable ampoule (5 mg/mL or 12.5 mg/mL) are useful for hospital staff education.

Safety Flowchart (Recommended Elements)

What should a quick decision flowchart contain?

Include the indication and an initial contraindications check for age and hypersensitivity.

Next show route choice with oral, buccal and parenteral branches and a baseline check for ECG if QT risk is present.

Add medication review prompts, dosing and monitoring steps, and clear adverse-event actions for EPS, hypotension and signs of neuroleptic malignant syndrome.

Patient counselling bullets should advise avoiding alcohol, not driving if drowsy and seeking urgent care for muscle stiffness or high fever.

Storage & Transport

How should Stemetil be stored and handled in practice?

Product information advises storage at room temperature between 15–30°C and protection from excessive moisture and light.

Tablets, buccal forms and suppositories are stable at ambient conditions while injectable ampoules require adherence to manufacturer handling instructions.

Pharmacy and hospital logistics should include controlled stock management, batch traceability and secure transport to preserve sterility of parenteral forms.

Patients should keep tablets in original packaging, store them away from children and avoid humid places such as bathrooms.

Prescriber Checklist

What must prescribers tick off before issuing Stemetil?

Confirm the indication and preferred route and check absolute contraindications including hypersensitivity and comatose states.

Review concomitant QT-prolonging drugs and other CNS depressants and adjust dose for elderly or liver and kidney impairment.

Provide written counselling and arrange a short-term follow-up within days for antiemetic use or 2–4 weeks for psychiatric indications.

Patient Counselling Points

What should patients be told when supplied prochlorperazine?

Explain how to take tablets (5–10 mg orally three to four times daily as required) and when buccal or parenteral routes are appropriate for rapid control.

Advise on missed doses — take when remembered unless the next dose is near and do not double doses.

Warn about sedation, dizziness and anticholinergic effects and instruct to stop the drug and seek urgent care for severe muscle stiffness, high fever or breathing difficulties.

Explain overdose signs such as excess sedation and hypotension and emphasise the need for hospital assessment.

Delivery Across United Kingdom

When To Choose Stemetil And When Not To

Which clinical scenarios favour prochlorperazine?

Prochlorperazine is a pragmatic choice for sudden, severe nausea where multiple formulations offer flexibility in route of administration.

Its low cost and ready availability as a generic make it attractive in primary care and palliative settings.

Ondansetron is preferable for chemotherapy or postoperative nausea where EPS risk is a major concern.

Metoclopramide should be considered when gastric stasis is suspected because of its prokinetic action.

Choice of agent should balance efficacy, side-effect profile and patient comorbidities.

Practical Notes For Community Pharmacists

How can community pharmacists support safe use of Stemetil?

Check indication, current medicines and any history of movement disorders or cardiac disease before supply or referral back to prescriber.

Advise on sedation and advise against driving or alcohol consumption during treatment.

For buccal forms instruct on correct placement and what to expect in terms of onset time compared with tablets.

Document counselling and encourage patients to seek urgent care for dystonia or severe adverse effects.

Storage And Return Advice For Patients

What should patients do with leftover or expired prochlorperazine?

Store all medicines at room temperature and protect them from light and moisture.

Do not dispose of unused medication in household waste or down the drain.

Use NHS guidance or local pharmacy take-back schemes for safe disposal of unused Stemetil or generics.

Keep all medicines out of sight and reach of children and store in original packaging where possible.

Final Practical Checklist For Prescribers

Quick safety steps before prescribing prochlorperazine.

Confirm indication and preferred route and verify no absolute contraindications such as hypersensitivity or comatose state.

Review current medications for QT risk and CNS depressant effects and reduce dose in elderly and those with hepatic or renal impairment.

Provide clear written instructions on dosing, sedation warnings and when to seek urgent medical help for dystonia or high fever.

Arrange follow-up appropriate to the indication and document the treatment plan.